Overview

Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
evaluate the differences in effectiveness and safety between CMAB807( potential biosimilar) and Prolia(original product)
Phase:
Phase 3
Details
Lead Sponsor:
Shanghai Biomabs Pharmaceutical Co., Ltd.
Treatments:
Denosumab